Agios Pharmaceuticals, Inc. (AGIO)
| Market Cap | 1.61B |
| Revenue (ttm) | 6.41M |
| Net Income (ttm) | -369.97M |
| Shares Out | 54.82M |
| EPS (ttm) | -6.43 |
| PE Ratio | n/a |
| Forward PE | 2.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 321,503 |
| Open | 29.45 |
| Previous Close | 28.98 |
| Day's Range | 29.07 - 30.31 |
| 52-Week Range | 16.75 - 50.98 |
| Beta | 1.18 |
| Analysts | Buy |
| Price Target | 35.19 (+19.5%) |
| Earnings Date | Nov 1, 2022 |
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is 35.19, which is an increase of 19.49% from the latest price.
News
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseas...
Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency i...
– Agios Expects a Decision on the Marketing Authorization Application by the European Commission within 67 Days of the Adoption of the Positive CHMP Opinion – – Agios Expects a Decision on the Marketing...
Agios to Participate in September Investor Conferences
CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined disease...
Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® ...
– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Regularly Transfused, PYRUKYND ® Demonstrated a Statistically Significant and Clinically Meaningful Reduction in Transfusion Burden –
Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors
CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today ...
Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) ...
– In Adults with Non-transfusion-dependent α- or β-Thalassemia, PYRUKYND ® Induced ≥1.0 g/dL Hemoglobin Increase from Baseline in 16 of 20 (80%) Patients Between Weeks 4-12 –
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer
CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today ...
Agios (AGIO) Q2 Loss Narrower Than Expected, Sales Beat
Agios Pharmaceuticals' (AGIO) posts encouraging results for the second quarter. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.62% and 64.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Agios Reports Business Highlights and Second Quarter 2022 Financial Results
– Generated $3.1 Million in Net U.S. Revenue for First Full Quarter of PYRUKYND ® (mitapivat) Sales –
Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today ...
Agios Appoints Brian Goff as Chief Executive Officer
– Current CEO, Jackie Fouse, Ph.D., to Transition to Chair of Board of Directors Effective August 8, 2022 –
Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficie...
– Treatment with PYRUKYND ® Associated with Early and Robust Hemoglobin Responses in Phase 3 ACTIVATE and Extension Studies; Approximately One-Third of Patients Achieved Normal Hemoglobin Levels at Leas...
Agios Announces Evolution of Research Organization
– Sarah Gheuens, M.D., Ph.D., to be Named Head of R&D, Chief Medical Officer; Chief Scientific Officer Bruce Car to Step Down at the End of July –
Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress
– Agios to Present New Patient-Reported Outcomes (PRO) Data from ACTIVATE Phase 3 Study of PYRUKYND ® (mitapivat) in Adults with PK Deficiency Who Do Not Receive Regular Transfusions –
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022
CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today a...
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.95% and 57.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Agios Reports Business Highlights and First Quarter 2022 Financial Results
– Received U.S. FDA Approval for PYRUKYND ® , the First Therapy for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) deficiency and Agios' First Genetically Defined Disease Medicine...
Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today...
Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PY...
– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Not Regularly Transfused, PYRUKYND ® Significantly Increased Hemoglobin Level, Decreased Hemolysis and Improved Patient-Reported Outcomes –
New Strong Sell Stocks for March 1st
AGIO, ALIM, and BV have been added to the Zacks Rank #5 (Strong Sell) List on March 1, 2022
Agios to Participate in March Investor Conferences
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today ...
Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil
Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Lags Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -5.85% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Agios Reports Fourth Quarter and Full Year 2021 Financial Results
– Received FDA Approval of PYRUKYND ® (mitapivat) for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) Deficiency; First Approved Therapy for this Rare Blood Disorder –